Nocturne Acquisition Corporation (MBTCR)
Price:
0.01 USD
( + 0.00 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
Churchill Capital Corp X
VALUE SCORE:
7
2nd position
Range Capital Acquisition Corp.
VALUE SCORE:
10
The best
M3-Brigade Acquisition V Corp. Units
VALUE SCORE:
10
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
No data to display
No data to display
No data to display
No data to display
No data to display
DESCRIPTION
Nocturne Acquisition Corporation intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses in the disruptive technology market. The company was incorporated in 2020 and is based in La Jolla, California.
NEWS
Nocturne Acquisition Corporation Announces Filing of a Registration Statement on Form S-4 in Connection with its Proposed Business Combination with Cognos
accesswire.com
2023-08-16 08:05:00Transaction Expected to Accelerate the Research and Advancement of Cognos' Proprietary and Innovative Implantable Drug Delivery Pump to Improve Outcomes for Treatment of Brain Cancers and Other Neurological Diseases WILMINGTON, DE / ACCESSWIRE / August 16, 2023 / Nocturne Acquisition Corporation (NASDAQ:MBTC)(NASDAQ:MBTCU)(NASDAQ:MBTCR) (the "Company", "MBTC" or "Nocturne"), today announced the submission via Edgar, the U.S. Securities and Exchange Commission's ("SEC") online portal, for filing of a registration statement on Form S-4 (the "Registration Statement") with the SEC, which includes a preliminary proxy statement/prospectus in connection with the proposed business combination (the "Business Combination") with Cognos Therapeutics, Inc. ("Cognos"), a medical technology company focused on developing unique, radically advanced devices for the treatment of neurological diseases including brain and spinal cancers, and degenerative neurological conditions (such as Alzheimer's and Parkinson's disease), epilepsy, and stroke. The Registration Statement contains a preliminary proxy statement/prospectus in connection with the previously announced Business Combination between Nocturne and Cognos.
Nocturne Acquisition Corporation Announces Filing of a Registration Statement on Form S-4 in Connection with its Proposed Business Combination with Cognos
accesswire.com
2023-08-16 08:05:00Transaction Expected to Accelerate the Research and Advancement of Cognos' Proprietary and Innovative Implantable Drug Delivery Pump to Improve Outcomes for Treatment of Brain Cancers and Other Neurological Diseases WILMINGTON, DE / ACCESSWIRE / August 16, 2023 / Nocturne Acquisition Corporation (NASDAQ:MBTC)(NASDAQ:MBTCU)(NASDAQ:MBTCR) (the "Company", "MBTC" or "Nocturne"), today announced the submission via Edgar, the U.S. Securities and Exchange Commission's ("SEC") online portal, for filing of a registration statement on Form S-4 (the "Registration Statement") with the SEC, which includes a preliminary proxy statement/prospectus in connection with the proposed business combination (the "Business Combination") with Cognos Therapeutics, Inc. ("Cognos"), a medical technology company focused on developing unique, radically advanced devices for the treatment of neurological diseases including brain and spinal cancers, and degenerative neurological conditions (such as Alzheimer's and Parkinson's disease), epilepsy, and stroke. The Registration Statement contains a preliminary proxy statement/prospectus in connection with the previously announced Business Combination between Nocturne and Cognos.